Comparative study on the clinical application of Epirubicin,gemcitabine combined with oxaliplatin in transcatheter hepatic arterial chemoembolization in the treatment of primary liver cancer
Objective:To study the clinical efficacy of epirubicin,gemcitabine and oxaliplatin combined with transcatheter hepatic artery chemoembolization in the treatment of primary liver cancer.Methods:A total of 121 patients with primary liver cancer treated in our hospital from January 2021 to January 2023 were selected as research objects,and divided into control group(n=56)and observation group(n=65)according to treatment methods.The control group was treated with liodol embolization,while the observation group was treated with epirubicin,gemcitabine and oxaliplatin by transcatheter hepatic artery chemotherapy.The short-term efficacy,Carcinoembryonic antigen(CEA)and alpha-fetoprotein(AFP)levels and the incidence of adverse reactions were analyzed and compared between the two groups.Results:After treatment,the total effective rate of observation group was significantly higher than that of control group(P<0.05).Serum CEA and AFP levels in observation group were significantly lower than those in control group(P<0.05).The total incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion:The application of epirubicin and gemcitabine combined with oxaliplatin in transcatheter hepatic arterial interventional chemotherapy can effectively improve the clinical therapeutic effect,reduce the level of tumor markers and attenuate adverse reactions.
EpiruloxacinGuitar NishihamaOxaliplatinHepatic arterial chemotherapyPrimary liver cancer
万方数据
维普
